Amylyx Pharmaceuticals Inc.

07/05/2022 | Press release | Distributed by Public on 07/05/2022 15:20

Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022